The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11151 malaria professionals are enjoying the free benefits of MalariaWorld today

immunogenicity

Immunogenicity and antigenic properties of Pf332-C231, a fragment of a non-repeat region of the Plasmodium falciparum antigen Pf332

April 22, 2010 - 12:03 -- Patrick Sampao
Author(s): 
H.A. Balogun, N.-M. Vasconcelos, R. Lindberg, M. Haeggström, K. Moll, Q. Chen, M. Wahlgren, K. Berzins
Reference: 
Vaccine, Volume 28, Issue 1, 10 December 2009, Pages 90-97

Detailed functional studies on the antigen have remained hampered by the cross-reactive nature of antibodies generated to Pf332. Pf332-C231, identified in the C-terminal region of Pf332 was cloned and antibodies against the C231 fragment were shown to react with intact Pf332 antigen by both immunofluorescence and immunoblotting analyses.

Vaxfectin® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses

March 31, 2010 - 11:19 -- Patrick Sampao
Author(s): 
Martha Sedegah, William O. Rogers, Maria Belmonte, Arnel Belmonte, Glenna Banania, Noelle B. Patterson, Denis Rusalov, Marilyn Ferrari, Thomas L. Richie, Denise L. Doolan
Reference: 
Vaccine, Volume 28, Issue 17, 9 April 2010, Pages 3055-3065

These data showing that Vaxfectin® can enhance the immunogenicity of plasmid DNA vaccines administered at low doses per body weight, and in combinations, has important clinical implications for the development of a vaccine against malaria, as well as against other public health threats.

Medical Treatment: 

Plasmodium falciparum Merozoite Surface Protein 1 (MSP-1)-MSP-3 Chimeric Protein: Immunogenicity Determined with Human-Compatible Adjuvants and Induction of Protective Immune Response

January 31, 2010 - 13:06 -- Ingeborg van Schayk
Author(s): 
Suman Mazumdar, Paushali Mukherjee, Syed Shams Yazdani, S. K. Jain, Asif Mohmmed, and Virander Singh Chauhan
Reference: 
Infect. Immun. 2010;78 872-883

A chimeric gene, MSP-Fu24, was constructed by genetically coupling immunodominant, conserved regions of the two leading malaria vaccine candidates, Plasmodium falciparum merozoite surface protein 1 (C-terminal 19-kDa region [PfMSP-119]) and merozoite surface protein 3 (11-kDa conserved region [PfMSP-311]).

Technology: 
Medical Treatment: 

Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.

December 3, 2009 - 12:11 -- Kabogo Ndegwa
Author(s): 
Manuel A. Giraldo, Gabriela Arevalo-Pinzon, Jose Rojas-Caraballo, Alvaro Mongui, Raul Rodriguez, Manuel A. Patarroyo
Reference: 
Vaccine, Volume 28, Issue 1, 10 December 2009, Pages 7-13, doi:10.1016/j.vaccine.2009.09.046.

In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. 

Medical Treatment: 

Immunogenicity and antigenic properties of Pf332-C231, a fragment of a non-repeat region of the Plasmodium falciparum antigen Pf332.

December 3, 2009 - 12:08 -- Kabogo Ndegwa
Author(s): 
H.A. Balogun, N.-M. Vasconcelos, R. Lindberg, M. Haeggström, K. Moll, Q. Chen, M. Wahlgren, K. Berzins
Reference: 
Vaccine, Volume 28, Issue 1, 10 December 2009, Pages 90-97, doi:10.1016/j.vaccine.2009.09.110

Antigen Pf332, a megadalton protein has been shown to be associated with the membrane of infected erythrocytes. Detailed functional studies on the antigen have remained hampered by the cross-reactive nature of antibodies generated to Pf332. Pf332-C231, identified in the C-terminal region of Pf332 was cloned and antibodies against the C231 fragment were shown to react with intact Pf332 antigen by both immunofluorescence and immunoblotting analyses. Antibodies to C231 inhibited in vitro Plasmodium falciparum growth efficiently.

Subscribe to RSS - immunogenicity